Genentech's Perjeta gets boost from final CLEOPATRA data
This article was originally published in Scrip
Roche/Genentech's humanized HER-2 targeting MAb Perjeta (pertuzumab) is set for a sales boost after final data from its Phase III CLEOPATRA study showed that it increased survival by 16 months when used in combination with Herceptin (trastuzumab) and docetaxel chemotherapy in previously untreated patients with HER-2 positive metastatic breast cancer.
You may also be interested in...
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.